Pharmaceutical conglomerate Merck has been issued a fine of $1.8 million by Brazilian antitrust authorities for engaging in pay-for-delay agreements.
Antitrust regulator CADE lodged the fine in response to Merck’s attendance at a meeting joined by top rivals Bayer, Abbott Laboratories, Bristol-Myers, Eli Lilly, Johnson & Johnson, Roche and more, say reports. The meeting allowed the companies to discuss paying generic drug makers to keep their competing products off pharmacy shelves, CADE found.
CADE also said that the other pharmaceutical companies were already fined years ago.
Merck argued that there was a lack of evidence in CADE’s decision and that it didn’t even sell generic drugs in Brazil until 2 years ago, after the meeting had occurred. Merck said it may appeal the ruling.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Reserve Greenlights Capital One’s $35.3 Billion Acquisition of Discover
Apr 18, 2025 by
CPI
Google to Appeal Partial Ruling in DOJ Antitrust Case
Apr 18, 2025 by
CPI
Indian Ad Agencies Warned Against WhatsApp Discussions After Antitrust Raids
Apr 17, 2025 by
CPI
US Court Ruling Against Google Spurs Fresh Antitrust Tensions in Europe
Apr 17, 2025 by
CPI
AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug
Apr 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet